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Introduction
Accumulating evidence suggests that
allergic rhinitis is a chronic inflammatory
disease instead of a disease of acute
symptoms. Therefore, even when
symptoms are absent, a minimal level
of inflammation may persist and the
treatment strategy may need to include
managing subclinical persistent
inflammation.1 If both inflammation and
hyper-responsiveness can persist
without symptoms, then symptoms can
no longer be considered the unique
markers of allergic disease.2
In fact, it has been shown that even
when exposure to allergens is too low
to provoke symptoms, there is still
inflammatory infiltration in the nasal
mucosa.3 The underlying goal of
treatment guidelines for allergic rhinitis
is the effective treatment of symptoms,
but this concept of minimal persistent
inflammation suggests a different
approach to therapy in which symptoms
can be considered the “tip of the
iceberg” of the allergic reaction with
inflammation and hyper-responsiveness
representing the submerged iceberg.4
There is compelling evidence that
a link exists between the upper and
lower respiratory tracts and that rhinitis
has a remarkable impact on asthma.
The inflammatory process which
develops in the nose and bronchi
explains some of the complex inter-
actions between different clinical
diseases such as rhinitis, sinusitis,
asthma, bronchial hyper-responsiveness
and viral infections.5  This suggests
some operative definitions: allergic
Rhino-bronchitis6, or United Airways
Disease7, or “one airway, one disease”8.
 The concept of CARAS (Combined
Allergic Rhinitis and Asthma Syndrome)
has important therapeutic implications.
 The occurrence of rhinitis in asthmatic
patients ranges from 70% to about 90%,
when strict criteria are used.9,10
The respiratory tract is a single
morpho-functional entity and is entirely
covered by ciliate epithelium and
mucinous glands down to the smallest
bronchi. The limits imposed by the
anatomical structures of nose and
bronchi must be taken into account.
The nose and paranasal sinuses are
rigid boxes where erectile sinusoids
predominate, whereas bronchi are
included in elastic parenchyma and
they are rich in smooth muscle tissue.
 Therefore, β2 agonists can resolve
asthma attacks but they have no effect
on rhinitis. On the contrary, H1 receptor
antagonists treat rhinitis symptoms, but
they are quite ineffective on broncho-
constriction. However, a synergistic
effect has been demonstrated for
antihistamines in association with
antileukotrienes.  The association could
reduce both rhinitis and asthma
symptoms.
Prevalence
Allergic rhinitis (intermittent or persistent)
must be distinguished from other forms
of rhinitis, i.e. infectious, vasomotor,
non-allergic rhinitis with eosinophilia
syndrome (NARES), occupational, drug-
induced, atrophic, and idiopathic.
Allergic rhinitis is the most common
form of respiratory allergy, affecting 15
to 20% of  the general population.
However, until the age of four years, a
clinical manifestation of IgE-mediated
allergy in the ears, nose and throat is
rare and the obvious expression of
allergic rhinitis is not seen until after the
age of four or five years.
The prevalence of allergic rhinitis is
greatest during the teenage years and
the early 20’s and decreases thereafter.
In the elderly it is generally non-
allergic mechanisms such as autonomic
imbalance, an alteration in muscarinic
receptors, or the sequelae of earlier
nasal disorders and their treatment that
are responsible. Allergic mechanisms
are rarely the cause of perennial rhinitis.
Nasal hyper-responsiveness in the
elderly may manifest as “old mans drip”,
a clear profuse watery rhinorrhoea which
forms a dewdrop at the end of the nose.
Mediators of symptoms
The classic allergic symptoms of
sneezing, nasal obstruction, pruritis and
rhinitis are produced by mediators
preformed in mast cells and rapidly
released (histamine, kinins), and by
mediators newly generated from the
arachidonic acid cascade when phos-
pholipid membranes are disturbed
( leukot r ienes,  pros tag landins ,
thromboxanes, eicosianoids).  Late-
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Abstract
Instead of considering allergic rhinitis as a disease of acute symptoms, it needs to be understood as a chronic
inflammatory disease that involves a level of persistent inflammation even in the absence of symptoms.  Given
the close functional, immunological and clinical link between asthma and rhinitis, it is reasonable to expect that
an effective treatment of rhinitis would affect the co-morbid asthma; the occurrence of rhinitis in asthmatic patients
ranges from 70% to about 90%.  The prevalence of allergic rhinitis in patients presenting to their primary care
providers with nasal symptoms is estimated to be 30% to 60%.  Diagnostic allergy testing is indicated only if the
test result could alter the decision to treat. Empirical treatment is a common approach, as allergic rhinitis is a
nonfatal disease with safe and effective treatments.  Nonsedating antihistamines and nasal steroids are relatively
free of side effects, and are reasonably inexpensive.  The nasal steroids reduce all symptoms, but the antihistamines
are less effective for nasal congestion and minimally address the problem of inflammation. Immune-based specifically
targeted molecules, such as the cloned humanised monoclonal antibody-inhibiting human IgE omalizumab, are
presently being studied in patients with seasonal allergic rhinitis.        (SA Fam Pract 2005;47(9): 22-26)
phase reactions, beginning 3 to 5 hours
after antigen exposure and peaking at
12 to 24 hours, are characterised by
nasal congestion and hyper-reactivity
caused by in f lammatory  ce l l
accumulation at the site of the previous
allergic reaction (allergen contact).1  As
early as two hours after allergen
exposure, eosinophil levels significantly
increase in nasal lavage fluids.
Eosinophil activation and their levels
are clearly essential to the allergic
imflammation.12 They release granules
containing toxic basic proteins, the
major part of which is represented by
eosinophil cationic protein (ECP), which
is measured in high levels in the nasal
fluid of patients with different upper
airway diseases.13 The cysteinyl
leukotrienes act through the Cys LT-
receptor and are important to the
chemotoxis of eosinophils.14  They have
also been reported to increase the
expression of histamine receptors on
macrophages and smooth muscle cells,
providing a mechanism for amplifying
responses to histamine.15
Diagnosis
The prevalence of allergic rhinitis in
patients presenting at primary care
facilities is estimated to be 30% to
60%.16 The disease probability is clini-
cally significantly increased if the patient
has been exposed to animal or pollen
triggers, or has a previous history of
allergy, or a family history of allergy.
The stereotypical signs and
symptoms of allergic rhinitis are usually
sufficient to arrive at the correct diag-
nosis.  However, laboratory testing to
confirm the clinical suspicion may be
useful when symptoms are perennial
instead of seasonal, or when patients
do not respond favourably to standard
treatment regimens. Skin tests (prick or
intradermal) are relatively inexpensive
while RAST, although expensive, is not
influenced by the presence of antihista-
mines.  As allergic rhinitis is a nonfatal
disease with effective treat-ment, it may
not be necessary to have absolute
precise estimates of allergy test
diagnostic performance.  Diagnostic
allergy testing is only indicated if the
test result could alter the decision to
treat.16  When patients do not respond
to medication and treatment must be
increased to incorporate allergen
avoidance and specific immunotherapy,
it is important to know what the allergen
is.  In this setting, allergy testing guides
treatment.
Untreated rhinitis symptoms may
lead to inability to sleep and chronic
malaise and fatigue, reduced capacity
for work and poor school preformance.
Patients are often plagued by a loss of
smell or taste caused by nasal oedema
and by postnasal drip with cough.
Structural facial and dental problems
can result from chronic allergic rhinitis.
 Constant upward rubbing of the nose
(allergic salute) can cause a permanent
transverse crease across the lower
nose.  Acute and chronic sinusitis are
relatively common complications of
allergic rhinitis.  Nasal polyps are less
common but bothersome. They require
both specific therapy and generally
improved management of the allergic
state.  The postnasal drip syndrome
(PNDS) is one of the most common
causes of chronic cough.
Treatment
Allergen avoidance is the mainstay of
therapy for many patients but is not
always practical. Regarding medication,
nonsedating antihistamines and nasal
steroids are relatively free of side effects,
and are reasonably inex-pensive.17,18
In children, the treatment should
focus predominantly on prevention and
be therapeutically as unagressive as
possible.  Allergen avoidance is an
effective means of preventing symptoms
triggered by indoor allergens such as
house dust mite, animals or mould.
Concomitant conjunctivitis frequently
occurs in children with seasonal rhinitis,
but is seldom reported in children with
chronic allergic rhinitis.
The treatment should be matched
to the symptoms.  Prophylactic treatment
to prevent the onset of significant
symptoms is preferable to trying to
control an ongoing problem, particularly
in patients with moderate to severe
disease. Oral antihistamines, nasal
antihistamines and decongestants are
initial treatment options for mild inter-
mittent rhinitis.  For moderate to severe
intermittent rhinitis, additional options
include a nasal steroid or cromone and
immunotherapy may be considered.
This also applies to mild persistent
rhinitis.  Patients with moderate to severe
persistent rhinitis should be started on
a nasal steroid and, on follow-up visit,
an antihistamine may be added for
itching and sneezing.  It may also be
necessary to add a decongestant on
short-term oral steroid for congestion,
but should the latter persist, a surgical
referral should be considered.  The
effect of medication treatment is
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Table I:  Effects of Medication Treatment.
0 = not effective for symptoms: + = mildly effective for symptoms: ++ = moderately effective for symptoms: +++ and ++++ = very effective for
symptoms. † = Do not use > 3-5 d.
displayed in Table I.19,20
Oral antihistamines, particularly the
newer non-sedating H1-receptor
antagonists (e.g. cetirizine, ebastine,
fexofenadine, loratadine and deslora-
tadine), are the primary agents in the
treatment of allergic rhinitis in children.
 These newer agents are as effective
as the older antihistamines in the
treatment of allergic rhinitis symptoms
except nasal blockage.  They are less
sedating and do not, in the elderly,
cause urinary retention and problems
of visual accommodation.  Antihista-
mines relieve sneezing, itching and
discharge and have minimal effects on
blockage.  They are important first-line
agents although less effective in one-
third to one-half of patients.  They
provide only partial symptom relief for
most patients, as histamine is only one
of many mediators causing allergic
rhinitis symptoms.  Topical antihistamines
(levocabastine, azelastine) have to be
administered two to four times a day.
Cromones (i.e. sodium cromoglycate
and nedocromil) reduce symptoms of
sneezing, rhinorrhoea and nasal itching
but tend to be less effective in the
prevention of nasal congestion.
Unfor tunately they have to be
administered four times a day and the
cromone must come into contact with
the entire mucous membrane.  Should
ten percent of the nasal lining not be
reached by the spray, symptoms could
possibly be evoked in the entire mucous
membrane.
Decongestants are used in combi-
nation with other agents, particularly
the antihistamines, to relieve nasal
blockage. Oral decongestants are
alpha-adrenergic agonists that act by
constricting blood vessels in the nasal
mucosa, but can also cause side-
effects, such as tremor, insomnia and
nervousness.  They may also aggravate
certain other medical conditions, such
as restricting urinary flow in males and
they are contra-indicated in patients
with hypertension of glaucoma. Topical
decongestants such as phenylephrine
and oxymetazoline relieve nasal
congestion. However, the risk of secon-
dary congestion allows only short-term
use. It is dangerous to give topical
vasoconstrictors to children under the
age of one year due to the narrow range
between therapeutic and toxic doses.
Intranasal corticosteroids are
considered first-line in allergic rhinitis,
because they relieve all the major nasal
symptoms, including blockage.  Since
they primarily affect the late phase of
the allergic reaction, they must be
administered prophylactically on a
regular basis.  Maximum benefit
appears during the second week of
treatment, with onset of relief usually
occurring after a week.
Intranasal absorption of the various
steroids from the relatively small
mucosal surface area is likely to be 30
to 40 percent of the deposited drug.
Systemic effects may thus be seen in
patients receiving concomitant treatment
with corticosteroids for rhinitis and
asthma. Although there is some reluc-
tance to prescribe topical cortico-
steroids to children with allergic rhinitis
because of concerns about long-term
systemic adverse effects, to date there
have been virtually no adverse reports
in the literature.  Ocular symptoms in
seasonal allergic rhinitis should be
controlled with the topical application
of cromoglycate or an antihistamine to
the eye.  The combination use of oral
antihistamines and intranasal cortico-
steroids, which appears to offer only a
marginal benefit compared with the use
of intranasal steroids alone, should be
reserved for patients with extensive hay
fever symptoms over and above nasal
symptoms.  The cost of combination
therapy should be carefully considered,
particularly longer term therapy.
Immunotherapy usually results in
only partial amelioration of symptoms.
It is expensive, requires long-term
treatment and compliance is poor.  It
should only be given to children who
are at least six to seven years old.  Strict
guidelines for specific immunotherapy
should be followed and suitable
candidates carefully selected to
maximise benefits.
Refer to a specialist
• Occupational rhinitis:  symptoms
occurring predominantly on work days.
• Nasal polyps:  bilateral chronic nasal
congestion with variable sneezing
and discharge but with significant
olfactory disturbance.
• Rhinitis medicamentosa:  persistent
rebound congestion as a result of
intranasal decongestant abuse.
• Malignancy:  continuous nasal
congestion, particularly if unilateral,
with bloodstained secretion or both.
• When specific immunotherapy is
being considered. 
See CPD Questionnaire, page 41
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